11:43 AM EST - Nuvo Research Inc. : Announced it has agreed with Horizon Pharma plc to extend the term of their manufacturing agreement for the production of PENNSAID® 2% for the U.S. market to December 31, 2029, which extends the agreement by an additional seven years. The amended agreement also provides for tiered pricing based on volumes of product supplied. Nuvo Research Inc.
shares T.NRI are trading down $0.55 at $6.55.
